VVY Stock Overview
A clinical stage biopharmaceutical company, engages in the research, development, and commercialize small molecule-based medicines. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Vivoryon Therapeutics N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.96 |
| 52 Week High | €9.93 |
| 52 Week Low | €0.41 |
| Beta | 2.02 |
| 1 Month Change | -6.00% |
| 3 Month Change | -6.44% |
| 1 Year Change | -75.89% |
| 3 Year Change | -89.90% |
| 5 Year Change | -61.94% |
| Change since IPO | -90.20% |
Recent News & Updates
Recent updates
We Think Vivoryon Therapeutics (AMS:VVY) Needs To Drive Business Growth Carefully
Dec 05
Here's Why We're Watching Vivoryon Therapeutics' (AMS:VVY) Cash Burn Situation
May 28Here's Why We're Watching Vivoryon Therapeutics' (AMS:VVY) Cash Burn Situation
May 04Companies Like Vivoryon Therapeutics (AMS:VVY) Are In A Position To Invest In Growth
Sep 02Here's Why We're Not Too Worried About Vivoryon Therapeutics' (AMS:VVY) Cash Burn Situation
Jan 26Companies Like Vivoryon Therapeutics (AMS:VVY) Are In A Position To Invest In Growth
Sep 16We Think Vivoryon Therapeutics (AMS:VVY) Can Afford To Drive Business Growth
May 10Is Vivoryon Therapeutics N.V.'s (AMS:VVY) Shareholder Ownership Skewed Towards Insiders?
Mar 11We're Hopeful That Vivoryon Therapeutics (AMS:VVY) Will Use Its Cash Wisely
Jan 14
Shareholder Returns
| VVY | NL Biotechs | NL Market | |
|---|---|---|---|
| 7D | -1.7% | 0.2% | -1.3% |
| 1Y | -75.9% | 15.5% | 3.6% |
Return vs Industry: VVY underperformed the Dutch Biotechs industry which returned 15.4% over the past year.
Return vs Market: VVY underperformed the Dutch Market which returned 5.5% over the past year.
Price Volatility
| VVY volatility | |
|---|---|
| VVY Average Weekly Movement | 18.7% |
| Biotechs Industry Average Movement | 7.6% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in NL Market | 6.9% |
| 10% least volatile stocks in NL Market | 2.3% |
Stable Share Price: VVY's share price has been volatile over the past 3 months compared to the Dutch market.
Volatility Over Time: VVY's weekly volatility has decreased from 29% to 19% over the past year, but is still higher than 75% of Dutch stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 15 | Frank Weber | www.vivoryon.com |
Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company’s lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer’s disease.
Vivoryon Therapeutics N.V. Fundamentals Summary
| VVY fundamental statistics | |
|---|---|
| Market cap | €51.09m |
| Earnings (TTM) | -€31.18m |
| Revenue (TTM) | n/a |
-14.1x
P/S Ratio-1.6x
P/E RatioIs VVY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VVY income statement (TTM) | |
|---|---|
| Revenue | -€3.62m |
| Cost of Revenue | -€525.00k |
| Gross Profit | -€3.09m |
| Other Expenses | €28.09m |
| Earnings | -€31.18m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.20 |
| Gross Margin | 85.50% |
| Net Profit Margin | 861.46% |
| Debt/Equity Ratio | 0% |
How did VVY perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 07:08 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Vivoryon Therapeutics N.V. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alexander Galitsa | Hauck Aufhäuser Investment Banking |
| Lucy-Emma Mary Codrington-Bartlett | Jefferies LLC |
| Christian Ehmann | Warburg Research GmbH |